| Literature DB >> 24699700 |
Lucia Palacios1, Helena Rosado1, Vicente Micol2, Adriana E Rosato3, Patricia Bernal1, Raquel Arroyo1, Helen Grounds4, James C Anderson4, Richard A Stabler5, Peter W Taylor1.
Abstract
Galloyl catechins, in particular (-)-epicatechin gallate (ECg), have the capacity to abrogate β-lactam resistance in methicillin-resistant strains of Staphylococcus aureus (MRSA); they also prevent biofilm formation, reduce the secretion of a large proportion of the exoproteome and induce profound changes to cell morphology. Current evidence suggests that these reversible phenotypic traits result from their intercalation into the bacterial cytoplasmic membrane. We have endeavoured to potentiate the capacity of ECg to modify the MRSA phenotype by stepwise removal of hydroxyl groups from the B-ring pharmacophore and the A:C fused ring system of the naturally occurring molecule. ECg binds rapidly to the membrane, inducing up-regulation of genes responsible for protection against cell wall stress and maintenance of membrane integrity and function. Studies with artificial membranes modelled on the lipid composition of the staphylococcal bilayer indicated that ECg adopts a position deep within the lipid palisade, eliciting major alterations in the thermotropic behaviour of the bilayer. The non-galloylated homolog (-)-epicatechin enhanced ECg-mediated effects by facilitating entry of ECg molecules into the membrane. ECg analogs with unnatural B-ring hydroxylation patterns induced higher levels of gene expression and more profound changes to MRSA membrane fluidity than ECg but adopted a more superficial location within the bilayer. ECg possessed a high affinity for the positively charged staphylococcal membrane and induced changes to the biophysical properties of the bilayer that are likely to account for its capacity to disperse the cell wall biosynthetic machinery responsible for β-lactam resistance. The ability to enhance these properties by chemical modification of ECg raises the possibility that more potent analogs could be developed for clinical evaluation.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24699700 PMCID: PMC3974817 DOI: 10.1371/journal.pone.0093830
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Structures of (-)-epicatechin gallate (ECg), (-)-epigallocatechin gallate (EGCg), (-)-epicatechin (EC), (-)-3,5-dihydroxy B-ring modified (-)-ECg (1), (-)-3-hydroxy B-ring modified (-)-ECg (2), (-) B-ring modified (-)-ECg (3), (-)- A,B-ring modified (-)-ECg (4) and A,B-ring modified (-)-Cg (5).
Oligonucleotide primers used for qRT-PCR.
| Gene | ORF | Forward primer | Reverse primer |
|
| SARr001 |
|
|
|
| SAR2126 |
|
|
|
| SAR1026 |
|
|
|
| SAR1831 |
|
|
|
| SAR0894 |
|
|
|
| SAR1030 |
|
|
|
| SAR2650 |
|
|
|
| SAR0273 |
|
|
|
| SAR0039 |
|
|
|
| SAR0739 |
|
|
|
| SAR1372 |
|
|
|
| SAR1729 |
|
|
|
| SAR1157 |
|
|
|
| SAR1461 |
|
|
|
| SAR1629 |
|
|
|
| SAR0652 |
|
|
|
| SAR1932 |
|
|
|
| SAR1034 |
|
|
|
| SAR1033 |
|
|
|
| SAR1964 |
|
|
|
| SAR0580 |
|
|
|
| SAR1974 |
|
|
|
| SAR1975 |
|
|
|
| SAR1976 |
|
|
|
| SAR0584 |
|
|
qRT-PCRa determination of changes to EMRSA-16 gene expression following exposure to ECg, EC and structural analogs of ECg.
| Gene | ORF | Function | ECg | EC | ECg/EC | 1 | 2 | 3 | 5 |
|
| SAR0894 | D-alanine-D-alanyl carrier protein ligase | 1.58* | 1.00 | 1.09 | 1.47 | 1.32 | 1.47 | 0.12* |
|
| SAR0039 | penicillin binding protein 2 prime | 1.36* | 1.18 | 1.15 | 1.37* | 1.49* | 0.88 | 0.23* |
|
| SAR1157 | penicillin binding protein 1 | 0.75 | 0.87 | 0.87 | 0.86 | 0.89 | 1.54* | 0.25* |
|
| SAR1461 | penicillin-binding protein 2 | 1.16 | 1.07 | 0.89 | 2.49* | 2.42* | 4.01* | 0.27* |
|
| SAR1629 | penicillin-binding protein PBP2B | 0.80 | 0.94 | 0.67 | 0.84 | 0.60* | 0.81 | 0.13* |
|
| SAR0652 | penicillin-binding protein 4 | 0.76* | 1.03 | 0.71* | 0.67* | 0.55* | 0.69 | 0.14* |
|
| SAR1932 | foldase protein PrsA | 3.44* | 1.00 | 2.77* | 4.57* | 4.96* | 7.85* | 1.04 |
|
| SAR1964 | monofunctional glycosyltransferase | 2.61* | 1.20 | 2.19* | 4.25* | 6.24* | 5.03* | 1.91* |
|
| SAR1974 | two-component response regulator | 2.21* | 1.63 | 1.72* | 3.66* | 1.95* | 5.69* | 0.86 |
|
| SAR1975 | two-component sensor histidine kinase | 2.20* | 0.65 | 1.51* | 4.95* | 2.41* | 11.01* | 0.92 |
|
| SAR1976 | response regulator | 2.93* | 0.97 | 2.24* | 3.10* | 2.90* | 5.81* | 0.91 |
|
| SAR1729 | cell shape determining protein MreC | 1.08 | 1.11 | 0.85 | 0.65* | 0.45* | 0.99 | 0.55* |
|
| SAR1372 | phosphatidylglycerol lysyltransferase | 2.23* | 1.59 | 2.26* | 1.49* | 1.89* | 1.81* | 0.48* |
|
| SAR2126 | accessory gene regulator protein A | 0.28* | 1.25 | 0.40* | 0.18* | 0.15* | 0.12* | 0.02* |
|
| SAR1831 | β-lactamase | 1.86 | 0.94 | 1.28 | 3.35* | 3.17* | 3.79* | 0.33* |
|
| SAR1026 | bifunctional autolysin | 0.74 | 1.27 | 0.81 | 0.91 | 0.70 | 0.71 | 0.05* |
|
| SAR1030 | protein FmtA | 1.81* | 1.36 | 1.56 | 1.44 | 0.90 | 0.90 | 0.08* |
|
| SAR2650 | immunodominant antigen A | 2.41* | 1.08 | 1.57 | 1.42 | 1.18 | 1.25 | 0.02* |
|
| SAR0273 | glycyl-glycine endopeptidase LytM | 3.16* | 1.40 | 2.86* | 3.60* | 5.63* | 4.87* | 0.04* |
|
| SAR0739 | HTH-type transcriptional regulator MgrA | 1.11 | 1.79 | 0.99 | 0.57* | 0.44* | 0.45* | 0.11* |
|
| SAR0580 | long chain fatty acid-CoA ligase VraA | 0.22* | 0.50* | 0.75* | 0.45* | 0.26* | 0.37* | 0.75 |
|
| SAR1034 | quinol oxidase subunit 2 | 0.43* | 0.43* | 0.25* | 0.31* | 0.23* | 0.14* | 0.03* |
|
| SAR1033 | quinol oxidase subunit 1 | 0.43* | 0.43* | 0.35* | 0.34* | 0.15* | 0.18* | 0.04* |
|
| SAR0584 | protein VraX | 17.46* | 1.09 | 14.39* | 34.77* | 40.29* | 62.35* | 7.31* |
Quantitative reverse transcription-polymerase chain reaction.
MRSA252 ORF identifiers for the BµG@S SAv1.1.0 microarray used in this study (39).
Refer to ECg analogs described in Fig. 1.
Denotes statistical significance p<0.05 (Student's t test, n = 6 in duplicate).
Figure 2Phenotypic changes induced by ECg.
Cytochrome c binding affinity and antibiotic susceptibility of S. aureus after exposure to ECg (▪) compared to untreated bacteria (□). Mid-logarithmic cultures of EMRSA-16 (A), EMRSA-16ΔmprF (B), EMRSA-16DAP4 (C) and EMRSA-16ΔmprFDAP4 (D) were exposed to ECg (12.5 μg/ml) for 4 h, the cells washed, incubated with cytochrome c (0.5 mg/ml) for 10 min and supernatants assayed spectrophotometrically at 530 nm (n = ≥4, ±1 SD). *p<0.001; **p<0.0001. For determination of minimum inhibitory concentration (MIC), ECg (12.5 μg/ml) was incorporated into the standard assay using MH broth containing 2% w/v NaCl (n = 4, ±1 SD).
Figure 3Effect of catechins on membrane fluidity of EMRSA-16.
The fluorescent probe DPH was incorporated into the CM as described under “Experimental Procedures”. A, fluorescence polarization (arbitrary units) before addition of ECg (bar 1), immediately after addition of 12.5 μg/ml ECg (bar 2) and after 1 (bar 3), 2 (bar 4), 3 (bar 5) and 4 h (bar 6) incubation at 37°C. B, fluorescence polarization after 4 h incubation with EC (bar 2), ECg (bar 3), ECg + EC (bar 4), compound 1 (bar 5), compound 2 (bar 6) and compound 3 (bar 7). Control (bar 1) before addition of ECg (n = ≥11, ±1 SD). *, p<0.01; **, p<0.001. All values compared to control (bar 1).
Figure 4Impact of catechins on the thermotropic behavior of model membranes.
Differential scanning calorimetry profiles of multi-lamellar LPG:PG:CL vesicles containing different concentrations of (A) EC, (B) ECg, (C) EC+ECg, (D) compounds 3 and 5 at a concentration of 20% total bilayer mass.
Figure 5Impact of catechins on anisotropy of model membranes.
Temperature variation of probe fluorescence anisotropy for DPH (A) and TMA-DPH (B) incorporated into LPG:PG:CL vesicles (•), and LPG:PG:CL vesicles containing either 20 mol% compound 3 (o), or 20 mol% compound 5 (◊). The DPH probe is located deep within the bilayer, whereas the TMA-DPH probe adopts a more superficial bilayer location. Compound 3 has almost no effect on anisotropy, but compound 5 elicits a major shift in the transition temperature and decreases anisotropy values in the gel phase and through the transition, indicating a decrease in lipid order and an increase in bilayer fluidity in comparison to compound 3 and vesicles alone.
Figure 6Localization of catechins within model membranes.
Stern-Volmer plots of quenching of (A) ECg, (B) EC, (C) EC+ECg, (D) compound 3, (E) compound 5 fluorescence with spin probes 5-NS (□) and 16-NS (▪) when incorporated into S. aureus model membranes. Quenching of (F) ECg, (G) EC, (H) ECg+EC, (I) compound 3, (J) compound 5 fluorescence with acrylamide, either in solution (o) or incorporated into LPG:PG:CL vesicles (•).